UNIGE document Scientific Article
previous document  unige:78632  next document
add to browser collection

Traitement combiné d'insuline et d'analogue du GLP-1 : qu'en attendre ?

Published in Revue médicale suisse. 2014, vol. 10, no. 433, p. 1235-1240
Abstract Type 2 diabetes mellitus is a progressive and heterogeneous disease. The decrease in insulin secretion by pancreatic beta cells and the increase of glucagon secretion by pancreatic beta cells, are the two major pathophysiologic characteristics. The majority of type 2 diabetics will therefore require insulin in the evolution of their disease, with weight gain and hypoglycaemia as side effects. GLP-1 analogs are effective therapeutic alternatives due to their actions on glucagon and insulin secretion, on satiety and gastric emptying. For patients inadequately controlled with conventional antidiabetics, GLP-1 analogs, introduced as an alternative or in combination with insulin, can prevent or reduce the side effects associated with insulin. Indeed, the risk of hypoglycaemia is reduced and the vicious circle of weight gain secondary to insulin/need to increase insulin doses is limited.
Keywords Diabetes Mellitus, Type 2/drug therapy/etiologyDrug Therapy, CombinationGlucagon-Like Peptide 1/analogs & derivativesHumansHypoglycemic Agents/administration & dosageIncretins/administration & dosageInsulin/administration & dosageMolecular Targeted Therapy
PMID: 25004768
Full text
Article (Published version) (669 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research group Diabète et régulation des gènes (36)
(ISO format)
DE KALBERMATTEN, Bénédicte Anne et al. Traitement combiné d'insuline et d'analogue du GLP-1 : qu'en attendre ?. In: Revue médicale suisse, 2014, vol. 10, n° 433, p. 1235-1240. https://archive-ouverte.unige.ch/unige:78632

425 hits

0 download


Deposited on : 2015-12-14

Export document
Format :
Citation style :